SARS-CoV-2 model shows Spike protein co-operation
A new coarse-grained model of the complete SARS-CoV-2 virion has revealed potential new ways to combat the coronavirus.
List view / Grid view
A new coarse-grained model of the complete SARS-CoV-2 virion has revealed potential new ways to combat the coronavirus.
Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
A study has shown that targeting the protein Nsp1 can inhibit genes for viral replication, which could lead to new COVID-19 treatments.
Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
Using NMR spectroscopy, researchers have partially observed the structure of heat shock proteins that bind to proteins that cause Huntington's disease.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
In a zebrafish model, researchers have found that the protein NAPMT can trigger muscle stem cells to proliferate and heal muscle damage.
Studies in mice have shown that the drug ProAgio is effective at treating pancreatic cancer and triple-negative breast cancer.
A new therapeutic approach using the protein IL-21 could optimise the immune system, allowing it to combat HIV.
New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.